All In Biotech

Drug Trial Radar · NCT04937153

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jun 15, 2021

Primary completion

Oct 1, 2024

Study completion Oct 1, 2024

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.

Conditions

  • Solid Tumor

Interventions

  • AcasunlimabBiological

    Acasunlimab will be administered intravenously (IV) once every 21 days.

  • PembrolizumabBiological

    Pembrolizumab will be administered IV once every 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose limiting Toxicities (DLTs)Time frame: During first cycle (Cycle length=21 days) in each cohort
  2. Number of Participants with Adverse Events (AEs)Time frame: From first dose date up to end of the safety follow up period, 90 days after last dose
  3. Area under the concentration time curve (AUC) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
  4. Maximum (Peak) Plasma Concentration (Cmax) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
  5. Time to Reach Cmax (Tmax) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
  6. Plasma Trough (Pre-dose) Concentrations (Cthrough) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
  7. Elimination half-life (t 1/2) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center East

    Chiba, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.